2019
IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA
Sun M, Orpilla J, Contreras E, Treger J, Molaie D, Tsang J, Antonios J, Wang A, Liau L, Prins R, Everson R. IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA. Neuro-Oncology 2019, 21: vi129-vi130. PMCID: PMC6847786, DOI: 10.1093/neuonc/noz175.542.Peer-Reviewed Original ResearchTCR-transduced T cellsNY-ESO-1 expressionNY-ESO-1Targeting NY-ESO-1Systemic adoptive transferAdoptive transferT cellsNY-ESO-1 mRNA expressionT cells in vitroSurvival benefit in vivoAdoptive transfer immunotherapyIncreased overall survivalIn vitro cytolysisMeningiomas in vitroHigher-grade meningiomasIn vivoReal-time cell analyzer systemAugment immunotherapyBenefit in vivoTumor cytolysisCT antigensImmunotherapeutic strategiesNSG miceOverall survivalImmunotherapy development
2016
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination
Hsu M, Sedighim S, Wang T, Antonios J, Everson R, Tucker A, Du L, Emerson R, Yusko E, Sanders C, Robins H, Yong W, Davidson T, Li G, Liau L, Prins R. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research 2016, 4: 412-418. PMID: 26968205, PMCID: PMC4873445, DOI: 10.1158/2326-6066.cir-15-0240.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell receptorT-cell receptor sequencingImmune responseOverall survivalPeripheral bloodIncreased time to progressionTumour-infiltrating lymphocytes contentAssessment of tumor-infiltrating lymphocytesPredictors of immune responseAntigen-specific immune responsesTime to progressionDendritic cell immunotherapyDC vaccinesCell immunotherapyImmunotherapeutic strategiesSurvival outcomesStatistically significant correlationT cellsClinical outcomesAdjunctive treatmentBrain tumorsImmunotherapyNext-generation sequencing approachTumor